MichaelA.RosenzweigMD

Oncology • Duarte, CA

Hematologic Oncology

Assistant Professor

Join to view full profile

Dr. Rosenzweig is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rosenzweig's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-301-8256

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Blood & Bone Marrow Transplant, 2009 - 2011
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Boston University Medical CenterResidency, Internal Medicine, 2001 - 2004
University of Arizona College of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2011 - 2025
NC State Medical License 2021 - 2022
NY State Medical License 2009 - 2013
MA State Medical License 2004 - 2011
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis Start of enrollment: 2013 Feb 01
Completed
Phase 1
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Completed
Phase 2
Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma Start of enrollment: 2019 Dec 11
Withdrawn
Phase 2
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma Start of enrollment: 2020 Oct 08
Active, not recruiting
Early Phase 1
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma Start of enrollment: 2020 Nov 27
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.
Raya Aliakbar, Olga Manouvakhova, Cindy Wong, Myo Htut, Johannes Pulst-Korenberg
Frontiers in Immunology. 2024-01-01
Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration.
Scott R Goldsmith, May San-Rozano, Justine Katindoy, Janet Rattanapichetkul, Michael Rosenzweig
Frontiers in Immunology. 2024-01-01
8 citations
Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant.
June-Wha Rhee, Raju Pillai, Tianhui He, Alysia Bosworth, Sitong Chen
JAMA Cardiology. 2024-01-01

Abstracts/Posters

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results
Michael Rosenzweig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Recommendations from FDA-AACR Workshop to Increase African American Representation in Multiple Myeloma Clinical TrialsApril 9th, 2021
Novel Approaches Emerge in AL AmyloidosisApril 27th, 2018
Working TogetherOctober 10th, 2017